by Zuzanna Fimińska

Bioelectronics is the field of developing medicines that use electrical impulses to modulate the body’s neural circuits as an alternative to drug-based interventions.

Last year, GSK created a venture capital fund called Action Potential Venture Capital, worth US$50m (£32m) aiming to invest in five to seven companies over the next five years in the hope to have the first medicine that “speaks the bioelectrical language of the [human] body” ready for approval in 2020. The fund’s first investment was SetPoint Medical, a US-based firm developing small implantable devices to treat inflammatory diseases, such as rheumatoid arthritis (RA).